Online Inquiry
Patient-Derived Xenograft (PDX) Model Development
Patient-derived xenograft (PDX) model has been recognized as an advanced preclinical oncology drug development model. At Alfa Cytology, we are committed to providing customized PDX mouse model development services.
Introduction to Patient-Derived Xenograft (PDX) Model
Patient-derived xenograft (PDX) model is a model composed of patient-derived cancer tissue inoculated into immunodeficient mice. The model retains the cellular and histopathological structure of the primary tumor, and the genome and gene expression profiles are largely preserved. The predictability of clinical efficacy reaches more than 80%, and it is currently recognized as the oncology research model with the highest accuracy. However, PDX models are particularly valuable due to the high cost of constructing PDX models, the fact that patients' cancer tissues or cells are not easy to obtain, the long tumor formation time, and the low tumor formation rate.
Types of Immunodeficient Model
Patient-derived xenograft (PDX) models are often required to be established in immunodeficient mice, thereby reducing rejection of transplanted tumors and increasing tumorigenicity. Immunodeficient mice are a class of mouse models that have defects in one or more components of the immune system due to congenital genetic mutations or artificial methods. Below are several commonly used immunodeficient mice.
| Model Types | Description |
| Nude Mouse | Abnormal development of the thymus due to a mutation in the Foxn1 gene, which lacks mature T cells and also affects B cell development. |
| SCID Mouse | Mutations in the gene that spontaneously encodes the catalytic subunit peptide of DNA-activated protein kinase (Prkdc) result in the inactivation of DNA repair enzymes that are key in the process of gene rearrangement of T- and B-cell receptors, and a lack of functional T and B cells. |
| NOD-SCID Mouse | Backcrossed with a non-obese diabetic mouse (NOD/Lt) strain on the basis of SCID mice with lower NK cell activity and lower chance of immune recovery. |
| NOG and NSG Mouse | Both mouse strains are defective in the IL2rg gene, resulting in a lack of mature T cells, B cells, and functional NK cells. |
Our Services
A large number of well-characterized patient-derived xenograft (PDX) models are becoming the research tool of choice in prostate cancer to optimize the drug development process, especially for target validation and translational studies. An integrated approach based on PDX in vitro, ex vivo, in vivo, and bioinformatics data will facilitate drug development and increase the pace of preclinical prostate oncology research. Alfa Cytology specializes in providing one-stop service for the patient-derived xenograft (PDX) models development.
Inoculation Sources
- Cell line
- Tissue
- Spheroid
- Organoid
Inoculation Method
- Subcutaneous
- In situ injection
- Subperitoneal
- Intravascular
Model Type Selection
- CRPC
- mCRPC
- mCSPC
- And More
Model Characterization
- Hhistopathology
- Immunohistochemistry
- Genetic profiling
- Molecular biomarkers
With professional technology platform and extensive experience in the industry, Alfa Cytology is committed to providing customers with high-quality mouse models and drug development services. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
For research use only.